This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Senesco To Present On SNS01-T At 54th American Society Of Hematology Annual Meeting

Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) announced today that two SNS01-T abstracts have been accepted for presentation at the 54 th American Society of Hematology (ASH) Annual Meeting and Exposition to be held on December 8-11 in Atlanta, Georgia. The abstracts are available on the ASH website at www.hematology.org.

“We are pleased that Dr. Lust, the PI at Mayo, will be providing an interim update on the encouraging results from the Phase 1b/2a trial,” stated Dr. Leslie J. Browne, President & CEO of Senesco. Dr. Browne continued, “Also there will be an opportunity for a detailed discussion of the striking results of combining SNS01-T with lenalidomide, the active ingredient in REVLIMID ®, in animal models of multiple myeloma and mantle cell lymphoma. The poster will be attended by Catherine Taylor from Senesco CSO John Thompson’s research laboratory at the University of Waterloo.”

Abstracts to Be Presented:

1.

   

“Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma” – Abstract # 53188 Sunday, December 9, 2012, 6:00 PM-8:00 PM, Hall B1-B2, Level 1, Building B (Georgia World Congress Center)

 

John A Lust, MD, PhD 1, Saad Z Usmani, MD FACP 2, Mehdi Hamadani, MD 3, Charles Barranco 4*, Martha Q Lacy, MD 1, Angela Dispenzieri, MD 1, Morie A Gertz 1, David Dingli, M.D., Ph.D. 1, Stephen Russell, MD, PhD 1*, Francis K Buadi, M.D. 1, Steven R Zeldenrust, MD, PhD 1, Suzanne R Hayman, MD 1, S. Vincent Rajkumar, MD 1, Shaji K. Kumar, MD 1, John Thompson 5*, Catherine A Taylor 5* and Richard Dondero 6*

 

1Division of Hematology, Mayo Clinic, Rochester, MN, 2Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 3Hematology/Oncology Bone Marrow Transplant, West Virginia University Hospitals, Inc., Morgantown, WV, 4Senesco Technologies, Inc., Bridgewater, NJ, 5Biology, University of Waterloo, Waterloo, ON, Canada, 6Senesco Technologies Inc., Bridgewater, NJ

 

2.

“Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma” – Abstract # 51240 Monday, December 10, 2012, 6:00 PM-8:00 PM, Hall B1-B2, Level 1, Building B (Georgia World Congress Center)

 

Catherine A Taylor 1, Terence Tang 1, Zhongda Liu 1, Sarah Francis 1, Zheng Qifa 1, Richard Dondero 2 and John Thompson 1,2

 

1Biology, University of Waterloo, Waterloo, ON, Canada 2Senesco Technologies Inc., Bridgewater, NJ

 

About Senesco Technologies, Inc.

Senesco, a leader in eIF5A technology, is sponsoring a clinical study to evaluate its lead therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma. SNS01-T targets B-cell cancers and selectively induces apoptosis by modulating eukaryotic translation initiation factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ commercialized products.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs